<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999553</url>
  </required_header>
  <id_info>
    <org_study_id>H18-00583</org_study_id>
    <nct_id>NCT04999553</nct_id>
  </id_info>
  <brief_title>Left vs. Right Non-Inferiority Trial</brief_title>
  <acronym>LeRNIT</acronym>
  <official_title>Left Intermittent Theta Burst Stimulation vs. Right Low Frequency Repetitive Transcranial Magnetic Stimulation Effectiveness in Depression and Suicidal Ideation: A Randomized Non-Inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the hypothesis that low-frequency rTMS (LFR) works as well&#xD;
      as the established intermittent thetaburst rTMS (iTBS) treatment for treatment resistant&#xD;
      depression (TRD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this multi-centre, triple-blinded, non-inferiority trial 420 patients with TRD will be&#xD;
      recruited at two academic centres (UBC, CAMH). Patients will be randomised to receive either&#xD;
      iTBS or LFR for 30 sessions. The primary outcome will be the improvement on a depression&#xD;
      scale. Secondary outcome will be improvement of suicidal ideation. A secondary aim is to test&#xD;
      the predictive capacity of a novel, easy to implement heart rate based biomarkers (i.e. heart&#xD;
      rate variability).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a two-arm multicenter parallel, clinician-blinded randomized non-inferiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Study doctors and raters obtaining outcome measures will be blind to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Depression severity</measure>
    <time_frame>30 days</time_frame>
    <description>17 item Hamilton Depression Rating Scale (HDRS-17) Change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Suicidal ideation</measure>
    <time_frame>30 days</time_frame>
    <description>Columbia Suicide Severity Rating Scale Screen Version (C-SSRS) Change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety severity</measure>
    <time_frame>30 days</time_frame>
    <description>Hamilton Anxiety Rating Scale (HAM-A) Change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression severity</measure>
    <time_frame>30 days</time_frame>
    <description>Self-rated 16-item Quick Inventory of Depressive Symptoms (QIDS-16) Change</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <condition>Major Depressive Episode</condition>
  <arm_group>
    <arm_group_label>Intermittent Theta Burst Stimulation (iTBS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iTBS to the L-DLPFC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Frequency Right (LFR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1Hz stimulation to the R-DLPFC</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>rTMS will employ the MagPro X100/R30 stimulator equipped with the cool-B70 as we used a cool-B70 in our past non-inferiority trial. The dose will be a 120% rMT in accordance to our latest trial using iTBS. The target area to stimulate will be the right dorsolateral prefrontal cortex (DLPFC) for LFR and the left DLPFC for iTBS as established in prior clinical trials. The localization of both targets will follow the well-established procedures for either R-DLPFC or L-DLPFC using a heuristic method.</description>
    <arm_group_label>Intermittent Theta Burst Stimulation (iTBS)</arm_group_label>
    <arm_group_label>Low Frequency Right (LFR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intermittent Theta Burst Stimulation (iTBS)</intervention_name>
    <description>Intermittent Theta Burst Stimulation (iTBS)</description>
    <arm_group_label>Intermittent Theta Burst Stimulation (iTBS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low Frequency Right (LFR)</intervention_name>
    <description>Low Frequency Right (LFR)</description>
    <arm_group_label>Low Frequency Right (LFR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. are female or male;&#xD;
&#xD;
          2. are outpatients;&#xD;
&#xD;
          3. are voluntary and competent to consent to treatment;&#xD;
&#xD;
          4. have a DSM 5 diagnosis of MDD,55 single or recurrent confirmed by Mini-International&#xD;
             Neuropsychiatric Interview (MINI) version 7.0;&#xD;
&#xD;
          5. are 18yo to 65yo;&#xD;
&#xD;
          6. have failed to achieve a clinical response to an adequate dose of an antidepressant&#xD;
             based on an Antidepressant Treatment History Form (ATHF) score of &gt; 3 in the current&#xD;
             episode OR have been unable to tolerate at least two separate trials of&#xD;
             antidepressants at less than the minimum adequate dose and/or duration (ATHF 1 or 2);&#xD;
&#xD;
          7. have a score â‰¥ 18 on the Hamilton Depression Rating Scale (HDRS-17 item);&#xD;
&#xD;
          8. have had no increase or initiation of any psychotropic medication in the 4 weeks prior&#xD;
             to screening;&#xD;
&#xD;
          9. are able to adhere to the treatment schedule;&#xD;
&#xD;
         10. pass the TMS and MRI adult safety screening questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. have a history of substance use within the last 3 months;&#xD;
&#xD;
          2. have a concomitant major unstable medical illness;&#xD;
&#xD;
          3. have active suicidal intent;&#xD;
&#xD;
          4. are pregnant;&#xD;
&#xD;
          5. have a lifetime (MINI) diagnosis of any psychotic or bipolar disorder;&#xD;
&#xD;
          6. have a MINI anxiety disorder or personality disorder assessed by a study investigator&#xD;
             to be primary and causing greater impairment than MDD;&#xD;
&#xD;
          7. have failed a course of ECT in the current episode;&#xD;
&#xD;
          8. have any significant neurological disorder, any history of seizure (except those&#xD;
             therapeutically induced by ECT), significant head trauma with loss of consciousness&#xD;
             for &gt; 5 min;&#xD;
&#xD;
          9. have any intracranial implant (e.g., aneurysm clips) or any other metal object within&#xD;
             or near the head, excluding the mouth, that cannot be safely removed;&#xD;
&#xD;
         10. are participating in psychotherapy, must have been in stable treatment for at least 3&#xD;
             months prior to study entry, with no anticipated change in the frequency of&#xD;
             therapeutic sessions, or focus of therapeutic sessions over the duration of the study;&#xD;
&#xD;
         11. have a clinically significant laboratory abnormality, in the opinion of the one of the&#xD;
             principal investigators;&#xD;
&#xD;
         12. have a non-correctable clinically significant sensory impairment (i.e., cannot hear&#xD;
             well enough to cooperate with interview);&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fidel Vila-Rodriguez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Afifa Humaira, BSc</last_name>
    <phone>604-827-1361</phone>
    <email>afifa.humaira@ubc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Avina, BSc</last_name>
    <phone>604-827-1361</phone>
    <email>michelle.avina@ubc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Non-Invasive Neurostimulation Therapies Centre, University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afifa Humaira, BSc</last_name>
      <phone>6048227308</phone>
      <email>afifa.humaira@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Fidel Vila-Rodriguez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J 1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Shim, MSc</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>30210</phone_ext>
      <email>Stacey.Shim@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel Blumberger, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Fidel Vila-Rodriguez</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>rTMS</keyword>
  <keyword>TMS</keyword>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <keyword>iTBS</keyword>
  <keyword>Depression</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

